Introduction: It is known that failures after midurethral slings increase with the follow-up time. Nevertheless, data concerning mini-slings are sparse. To clarify this statement, we analyze a mini-sling cohort with a median follow-up of 10 years. Although the brand used, MiniArc®, is no longer available, an identical device, Solyx™, can still be used, which makes the analysis of the cohort clinically relevant. Material and Methods: A total of 172 women with predominant stress urinary incontinence (SUI) were consecutively treated with the mini-sling MiniArc® from 2006 until 2013. They were reevaluated in 2018. The primary outcome, treatment success, was defined as no self-reported SUI symptoms and no reintervention. Secondary outcomes included the response to patient-reported outcomes. Adverse events were assessed. Results: After a median follow-up time of 113 months, 115 (66.9%) women were available for reevaluation. Forty-four (38.3%) women self-reported SUI. Seventeen women had been reoperated, 14 (12.2%) due to the reappearance of SUI and 3 due to complications. Altogether, MiniArc® had an overall success rate of 47.0% at 10 years. Among those not reoperated, 63.3% stated that they were much better or very much better in Patient Global Impression of Improvement (PGI-I) and 71.4% affirmed that their continence problem was normal or mild in Patient Global Impression of Severity (PGI-S). Almost 85% would repeat the surgery. Reoperation due to complications was rare (2.6%). De novo urgency appeared in 30.6% of the patients and it was managed with anticholinergic drugs with favorable outcomes. Discussion/Conclusion: This report adds evidence to the long-term outcomes of mini-slings, confirming that they can cure or improve SUI and give patients high satisfaction rates, at the expense of low morbidity.

1.
Abrams
P
,
Cardozo
L
,
Fall
M
,
Griffiths
D
,
Rosier
P
,
Ulmsten
U
, et al.
The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society
.
Neurourol Urodyn
.
2002
;
21
(
2
):
167
78
. .
2.
Wein
A
,
Kavoussi
L
,
Partin
A
,
Peters
C
.
Campbell-Walsh urology
. 11th ed.
St Louis
:
Elsevier
;
2016
.
3.
Burkhard
F
,
Bosch
J
,
Cruz
F
, et al.
Guidelines on urinary incontinence
.
European Association of Urology
;
2018
.
Available from:
.
4.
Rechberger
T
,
Futyma
K
,
Jankiewicz
K
,
Adamiak
A
,
Skorupski
P
.
The clinical effectiveness of retropubic (IVS-02) and transobturator (IVS-04) midurethral slings: randomized trial
.
Eur Urol
.
2009
;
56
(
1
):
24
30
. .
5.
Richter
HE
,
Albo
ME
,
Zyczynski
HM
,
Kenton
K
,
Norton
PA
,
Sirls
LT
, et al.
Retropubic versus transobturator midurethral slings for stress incontinence
.
N Engl J Med
.
2010
;
362
(
22
):
2066
76
. .
6.
Kenton
K
,
Stoddard
AM
,
Zyczynski
H
,
Albo
M
,
Rickey
L
,
Norton
P
, et al.
5-year longitudinal followup after retropubic and transobturator mid urethral slings
.
J Urol
.
2015
;
193
(
1
):
203
10
. .
7.
Jiao
B
,
Lai
S
,
Xu
X
,
Zhang
M
,
Diao
T
,
Zhang
G
.
A systematic review and meta-analysis of single-incision mini-slings (MiniArc) versus transobturator mid-urethral slings in surgical management of female stress urinary incontinence
.
Medicine
.
2018
;
97
(
14
):
e0283
. .
8.
Bai
F
,
Chen
J
,
Zhang
Z
,
Zheng
Y
,
Wen
J
,
Mao
X
, et al.
Adjustable single-incision mini-slings (Ajust®) versus other slings in surgical management of female stress urinary incontinence: a meta-analysis of effectiveness and complications
.
BMC Urol
.
2018
;
18
(
1
):
44
.
9.
Mostafa
A
,
Lim
CP
,
Hopper
L
,
Madhuvrata
P
,
Abdel-Fattah
M
.
Single-incision mini-slings versus standard midurethral slings in surgical management of female stress urinary incontinence: an updated systematic review and meta-analysis of effectiveness and complications
.
Eur Urol
.
2014
;
65
(
2
):
402
27
. .
10.
Schellart
RP
,
Zwolsman
SE
,
Lucot
JP
,
de Ridder
DJMK
,
Dijkgraaf
MGW
,
Roovers
JWR
.
A randomized, nonblinded extension study of single-incision versus transobturator midurethral sling in women with stress urinary incontinence
.
Int Urogynecol J
.
2018 Jan
;
29
(
1
):
37
44
. .
11.
Tutolo
M
,
de Ridder
DJ
,
Montorsi
F
,
Castagna
G
,
Deprest
J
,
Schellart
RP
, et al.
A minimum of 1-year follow-up for MiniArc single incision slings compared to Monarc transobturator slings: an analysis to evaluate durability of continence and medium-term outcomes
.
Neurourol Urodyn
.
2017 Mar
;
36
(
3
):
803
7
. .
12.
Oliveira
R
,
Resende
A
,
Silva
C
,
Dinis
P
,
Cruz
F
.
Mini-arc for the treatment of female stress urinary incontinence: long-term prospective evaluation by patient reported outcomes
.
ISRN Urol
.
2014
;
2104
:
659383
. .
13.
Yalcin
I
,
Bump
RC
.
Validation of two global impression questionnaires for incontinence
.
Am J Obstet Gynecol
.
2003
;
189
(
1
):
98
101
. .
14.
Kim
A
,
Kim
MS
,
Park
YJ
,
Choi
WS
,
Park
HK
,
Paick
SH
, et al.
Clinical outcome of single-incision slings, excluding TVT-Secur, vs standard slings in the surgical management of stress incontinence: an updated systematic review and meta-analysis
.
BJU Int
.
2019 Apr
;
123
(
4
):
566
84
.
15.
Nambiar
A
,
Cody
JD
,
Jeffery
ST
,
Aluko
P
.
Single-incision sling operations for urinary incontinence in women
.
Cochrane Database Syst Rev
.
2017
;
7
(
7
):
CD008709
. .
16.
Serati
M
,
Braga
A
,
Athanasiou
S
,
Tommaselli
GA
,
Caccia
G
,
Torella
M
, et al.
Tension-free vaginal tape-obturator for treatment of pure urodynamic stress urinary incontinence: efficacy and adverse effects at 10-year follow-up
.
Eur Urol
.
2017 Apr
;
71
(
4
):
674
9
. .
17.
Natale
F
,
Illiano
E
,
Marchesi
A
,
La Penna
C
,
Costantini
E
.
Transobturator tape: over 10 years follow-up
.
Urology
.
2019 Jul
;
129
:
48
53
. .
18.
Schauer
I
,
Bock
H
,
Eredics
K
,
Wallis
M
,
Scholz
M
,
Madersbacher
S
, et al.
10 years follow-up after mid-urethral sling implantation: high rate of cure yet a re-occurrence of OAB-symptoms
.
Neurourol Urodyn
.
2017 Mar
;
36
(
3
):
614
9
. .
19.
Marcelissen
T
,
Van Kerrebroeck
P
.
Overactive bladder symptoms after midurethral sling surgery in women: risk factors and management
.
Neurourol Urodyn
.
2018
;
37
(
1
):
83
8
. .
20.
Milsom
I
,
Abrams
P
,
Cardozo
L
,
Roberts
RG
,
Thüroff
J
,
Wein
A
.
How widespread are the symptoms of an overactive bladder and how are they managed? A population based prevalence study
.
BJU Int
.
2001
;
87
(
9
):
760
6
.
21.
Irwin
D
,
Milsom
I
,
Hunskaar
S
,
Reilly
K
,
Kopp
Z
,
Herschorn
S
, et al.
Population-based survey of urinary incontinence, overactive bladder and other lower urinary tract symptoms in five countries: results of the EPIC study
.
Eur Urol
.
2006
;
50
(
6
):
1306
15
.
22.
Coyne
KS
,
Sexton
CC
,
Vats
V
,
Thompson
C
,
Kopp
ZS
,
Milsom
I
.
National community prevalence of overactive bladder in the United States stratified by sex and age
.
Urology
.
2011
;
77
(
5
):
1081
7
. .
23.
Irwin
DE
,
Milsom
I
,
Chancellor
MB
,
Kopp
Z
,
Guan
Z
.
Dynamic progression of overactive bladder and urinary incontinence symptoms: a systematic review
.
Eur Urol
.
2010 Oct
;
58
(
4
):
532
43
. .
24.
Chapple
CR
,
Cruz
F
,
Deffieux
X
,
Milani
AL
,
Arlandis
S
,
Artibani
W
, et al.
Consensus Statement of the European Urology Association and the European Urogynaecological Association on the use of implanted materials for treating pelvic organ prolapse and stress urinary incontinence
.
Eur Urol
.
2017 Sep
;
72
(
3
):
424
31
. .
25.
Boyers
D
,
Kilonzo
M
,
Mostafa
A
,
Abdel-Fattah
M
.
Comparison of an adjustable anchored single-incision mini-sling, Ajust, with a standard mid-urethral sling, TVT-O (TM): a health economic evaluation
.
BJU Int
.
2013 Dec
;
112
(
8
):
1169
77
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.